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ABSTRACT 
Background: Cyclic adenosine monophosphate (cAMP)  dependent protein kinase A plays major role in cell signalling 
to undergo many cellular functions. Over expression of extracellular cAMP dependent protein kinase catalytic subunit 
alpha (PRKACA) causes severe tumorgenesis in prostate. Thus, computer aided high throughput virtual screening and  
molecular dynamics simulations studies were implemented to identify the potent leads for human PRKACA. 
Methods:    The  human  PRKACA  crystal  structure  was  optimized  in  Maestro  v9.2.    Fifteen  recently  published 
PRKACA inhibitors were selected for compiling 5388 structural analogs from Ligand.Info database, these  were pre- 
pared  using  LigPrep.  Molecular  docking  from  lesser  to  higher  stringency towards  minor  steric  classes  was  applied 
subsequently to the prepared ligand dataset into PRKACA active site using Glide v5.7. Molecular dynamics simulation 
studies were done using Desmond v3.0 to predict the activity of PRKACA-leptosidin complex. 
Results:  Twenty  lead  molecules  were  identified.  Lead-1  was  observed  to  have  relatively  the  least  docking  score 
compared to the identified lead molecules and 15 published inhibitors. The PRKACA- leptosidin complex deciphered 
that  leptosidin  blocked  the  active  site  residues  Thr-51,  Glu-121,  Val-  123,  Glu-127  and  Thr-183  directly  through 
intermolecular  hydrogen  bonds.   In  molecular  dynamics  simulations, trajectory analysis also  showed  existence of 
water bridges between PRKACA and leptosidin.  
Conclusions:  Docking  and  molecular  dynamics  studies  revealed  the  better  binding  interaction  of  leptosidin  with 
PRKACA. Leptosidin is having the better pharmacological properties thus it could be a futuristic perspective chemical 
compound for prostate cancer therapy. 
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INTRODUCTION 
The  human  genome  contains  about  500 
protein kinase  genes.  Protein  kinases  belong 
to  tran  ferase  family,  which  get  activated 
through  phosphorylation  reactions.  The 
activated  protein  kinases  regulate  many 
biological  processes  like  gene  expression, 
signaling  mechanisms,  cell  regulation  and 
extra-intra cellular stimuli.
1   Mutations,  halted 
cellular  inhibition  and  overexpression  or 
down regulation of protein kinases can result 
in acute diseases such as cancer, diabetes and 
deficiency in the immune system.
2,3   Cancer  is 
a  result  of  tumorgenesis due to genetic and 
epigenetic  alterations  which  lead  to 
transformation of normal cells into malignant 
cells. Protein kinases have vital role in 
tumorgenesis  and  cell  progression,  hence, 
more  than  70  kinase  inhibitors  are  under 
clinical trials against cancer.
4 Most inhibitors 
of protein kinases were developed by targeting 
on the ATP binding site. 
5-7 
The  cAMP  (cyclic  adenosine  mono 
phosphate) dependent protein kinase catalytic 
alpha subunit (PRKACA) of  protein 
kinase  A  (PKA)  belongs  to  serine/threonine 
kinase  family.  The  holoenzyme  of  human 
PKA  has  three  types  of  catalytic  subunits 
namely  Cα  Cβ,  and  Cγ
8-10 and four types of 
regulatory subunits RIα, RIβ, RIIα and RIIβ.
11-
14  In catalytic core motif, amino cleft involved 
in  Mg-ATP  binding  site,  where  as  carboxy 
cleft involved in peptide binding (regulator of 
C  subunit  activity)  and  catalysis.  Activation 
of PKA depends on concentration levels of 
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cAMP. Glucagon receptors bind with the G-
proteins  and  the  formed  complex  coupled 
with the adenylate cyclase becomes active to 
further act on ATP for release of cAMP. The 
released cAMP binds to regulatory subunits 
and results in free catalytic subunits. The free 
catalytic subunits can catalyse the transfer of 
ATP terminal phosphates to protein substrates 
at  serine (or)  threonine  residues.  PKAs  are 
present  in  a  variety  of  cells, acts on various 
substrates  to  participate  in  metabolism,
15  
gene regulation,
16  cell growth and division,
17  
cell  differentiation,
18,19   sperm  motility
20  and 
ion  channel  conductivity,
21    among  others. 
Thus,  minute  alteration  in  the  catalytic 
subunit of PKA would hamper cell signalling 
mechanism leading to cancer. 
Experimental  studies  revealed  that  over  ex- 
pression  of  extracellular  PKA  catalytic 
subunit  causes  severe  tumorgenesis  in 
prostate  cancer  and  other  cancers.
22,23  
Therefore, PRKACA is being used as a drug 
target  for  various  cancers.  Quite  a  few 
inhibitors  of  PRKACA  are  under  clinical 
trials.   The present study was carried out for 
discovery  of  new  class  of  PRKACA 
inhibitors with good pharmacokinetic proper- 
ties using high throughput virtual screening 
and molecular dynamics simulations. 
MATERIAL AND METHODS 
Protein preparation 
Co-crystal structure of human PRKACA with 
“796”,  an  inhibitor  was  retrieved  from  the 
protein  data  bank  (PDB).
24  The  PRKACA 
structural  features,  active  site  residues  and 
catalytic  residues  were  analyzed  using 
PDBsum
25. Maestro v9.2 protein preparation 
wizard  was  used  to  fix  erroneous  atomic 
representations in crystal  structure  and  its  
optimization.
26  The  bond  orders  were 
assigned  to  residues  of  proteins,  hydrogen 
atoms  were  added  and  tautomeric  states 
taking  place  at  their  normal  pH  (7.0)  were 
generated.  Protonation  states  of  hydroxyl, 
histidine groups, “flips” of C/N atom and side 
chain  O/N  atom  of  the  protein  were 
optimized.  Impref  minimization  was  carried 
out using the OPLS (Optimized Potentials for 
Liquid  Simulations)  2005  molecular 
mechanics  force  field
27  with  cut  off  RMSD
(Root Mean Square Deviation) of 0.3 Å. A 
20×20×20  Å  receptor  grid
28  was  generated 
around  the  active site and catalytic residues 
of the refined human PRKACA protein using 
Glide v5.7.
29
 
Structural analogs search 
A  geometry  based  analog search  for  fifteen 
published inhibitors of PRKACA (BIRB-796, 
LY333531,  MLN-518,  SB202190, 
SB203580,  flavopiridol,  roscovitine, 
gleevec,
30  H89,  HA1077,  KN62,  
Mallotoxin,
31Balanol,
32      Go-6983,  PP-2
33) 
was  performed  in  Ligand  Info  Meta 
database. Ligand.info provides a user friendly 
java based tool to find structural analogs  of 
ligands  from  eight  databases 
(ChemBank,  ChemPDB,  KEGG  Ligand, 
Anti-  HIV  NCI  (National  Cancer  Institute), 
Drug- likeness   NCI,   Not annotated   NCI, 
AKos  GmbH  and  Asinex  Ltd)  comprising 
more than one million small molecules.
34,35  It 
can interactively cluster sets of molecules on 
the user side and automatically download the 
similar molecules from the server. 
Ligand preparation 
LigPrep
36  is a tool in Schrödinger suite used 
to  generate  the  3D  structures  from  2D 
representation, searching for tautomers, steric 
isomers,  ionizations  states  using  Epik
37  
followed  by  geometry  minimization  of 
ligands  based  upon  the  OPLS  2005  force 
field.
27  The  ligands  with  poor 
pharmacological properties and reactive func 
tional  groups  were  discarded  applying 
Lipinski„s filter and reactive filter and an in-
house  library  of  non-redundant, 
pharmacologically  preferred  conformations 
were prepared. 
Computational docking 
Docking  is  a  procedure  to  predict  the 
preferable  binding  orientation  between  the 
two molecules to form a stable complex. 
38 
Docking calculations were carried out using 
Glide  v5.7.
29  The  prepared  and  optimized 
ligands were flexibly docked in the grid box 
of  the  protein  using  MCSA  (Monte  Carlo 
based  simulated  algorithm)  based 
minimization. Glide Score (GScore) was used 
for representing binding affinity and ranking. 
Three subsequent docking procedures such as 
high  throughput  virtual  screening  (HTVS), 
standard precision (SP) and extra precision  
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(XP)
26,39  were  implemented  to  retain  lead 
molecules  with  better  binding  affinity  in  a 
good binding orientation without steric classes. 
10,000  poses  were  generated  during  XP 
docking for each ligand and the best pose was 
retained after post docking minimization. The 
molecules  which  are  docked  favorably  were 
ranked based on the XP Gscore. 
Molecular dynamics 
Molecular  dynamics  (MD)  simulations  for 
docking complex of human PRKACA – lead1 
were  performed  using  Desmond  3.2
40,41as 
implemented in Schrödinger package with 10 
ns (nanoseconds) simulation time. The initial 
steps  of  MD  simulations  were  performed  by 
applying  OPLS  2005  molecula  mechanics 
force field.
27 Water molecules were placed to 
the ligand-receptor complex with simple point 
charge  (SPC)  water  model.  System  was 
neutralized  with  counter  ions,  SHAKE 
algorithm
42 used to constrain the geometry of 
water molecules and heavy atom bond lengths 
with  hydrogens,  electrostatic  interactions 
applied  using  particle  mesh  ewald  (PME) 
method
43  and  periodic  boundary  conditions 
(PBC) were used.
43
 
The full system of 44,164 atoms was simulated 
through the multistep MD protocols of Maestro 
v9.2.  Briefly, full system minimization with 
restraints  on  solute  was  performed  for 
maximum  2000  iterations  of  a  hybrid  of  the 
steepest  descent  and  the  limited  memory 
Broyden  -  Fletcher  -  Gold  farb-Shanno 
LBFGS)  algorithms,  with  a  convergence 
threshold  of  50.0  kcal/mol/Å.
2
  Similar 
minimization  without  any  restraints  was 
performed with a convergence threshold of 5.0 
kcal/mol/Å.
2 Non hydrogen solute atoms were 
restrained  in  the  NVT  ensemble  (constant 
number of atoms N, volume V and temperature 
T) using 10 picoseconds (ps) simulation time 
and    temperature  of  10K.  Simulations 
restraining  non  hydrogens  solute  atoms  were 
performed  in  the  NPT  ensemble  (constant 
number  of  atoms  N,  pressure  P  and 
temperature T) for 12 ps simulation time and 
temperature  of  10K.  Further,  NPT  ensemble 
for a simulation time of 24 ps restraining all 
nonhydrogen solute atoms (temperature 300K)  
 
 
and  NPT  ensemble,  without  restraints,  for  a 
simulation time of 24 ps (temperature 300K) 
was performed to relax the system.   
The relaxed system was simulated for a simu- 
lation time of 10000 ps with a time step of 2 
femtosecond  (fs),  NPT  ensemble  using  a 
Berendsen  thermostat  at  310  K  and  velocity 
resampling  for  every  1ps.  Trajectories  after 
every  4.8  ps  were  recorded.  Energy 
fluctuations and RMSD of the complex in each 
trajectory  were  analyzed  with  respect  to 
simulation time. The backbone and side chain 
root mean square fluctuations (RMSF) of each 
residue  PRKACA  were  monitored  for 
consistency.  The  inter-molecular  interactions 
of lead1-PRKACA were assessed for stability 
of the docking complex. 
RESULTS 
Structural analysis of PRKACA 
The co-crystal structure of PRKACA in com- 
plex with 796
24  provides novel insight to de- 
velop a new class of inhibitor designing. The 
protein  is  of  351  residues  and  comprises  of 
15 helices and 14 strands (Figure 1A). Asp166, 
Lys168,  Glu170,  Asn171  and  Thr201  were 
reported as catalytic  residues in catalytic site  
atlas    (CSA)    annotation    (Figure  1A).  The 
residues such as Leu49, Gly50, Thr51, Gly52, 
Gly55, Arg56, Ala70, Lys72, Ile73, Leu74, Val 
103,  Met120,  Glu121,  Tyr122,  Val123, 
Asn171, Leu173, Thr183, Asp184 and Phe327 
were  localized  to  be  in van der Waal contact 
with “796” constitute as the active site residue 
(Figure  1A).      PRKACA  residues  Leu49, 
Thr51,  Gly52,  Gly55,  Arg56,  Ala70,  Lys72, 
Val104,  Met120,  Glu121,  Tyr122,  Val123, 
Asn171, Leu173, Thr183, Asp184 and Phe327 
were  involved  in  hydro  phobic  interactions 
with    „796‟  (Figure    1B).  The  ligand  „796‟ 
formed four H-bonds with the  residues 
Glu121,  Val123,  Asn171  (catalytic  residue) 
and Asp184 (Figure 1B). Further, assessments 
CASTp  analysis  supported  the  role  of  these 
residues  to  form  binding  pocket  in  human 
PRKACA. 
Ligand dataset optimization 
Compounds  with  similar  structural  geometry 
would deliver the similar effects;
29,30 therefore, 
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small  molecule  databases  directly, it  is  better 
to  implement  docking  methods  to  a  set  of 
structural  analogs  for  published  inhibitors  for 
identification  of  new  class  of  inhibitors. 
Simplified molecular input line entry (SMILE) 
specification  formats  of  15.  PRKACA 
published  inhibitors  were  imported  in  to 
Ligand.info tool and 5388 structural analogues 
were  obtained.  The  structural  analogues  were 
converted to their 3D structural forms. Multiple 
conformation generation of each analogue (3D 
structure)  was  produced  with  20494  ligand 
conformers.    The  conformations  with  higher 
energetic state, not following  Lipinski„s rule  of  
five  and  include  reactive  functional groups 
were  discarded  from  the  dataset  and 7470 
non-redundant  pharmacologically  preferred 
conformations  were  retained  for  virtual 
screening. 
Virtual screening 
One of the most widely used methods for high 
throughput  virtual  screening  is  docking  of 
small molecules into active site of protein tar- 
get  and  subsequent  scoring.  A  wide  range  of 
different docking programs are available, most 
of  which  use  semi-rigid  docking,  where  the 
ligands are treated as flexible and the receptors 
as  rigid.  Glide  v5.7  is  one  of  the  efficient 
docking  programs  widely  used  for  fast  and 
extremely accurate binding mode predictions of 
ligands  with  protein.  Maestro  v9.2  virtual 
screening workflow implements three modes of 
Glide  docking  to  make  the  new  class  of 
inhibitor searching procedure fast and efficient. 
The docking modes penalizes lesser to higher 
towards minor steric classes from HTVS to XP 
docking.  Each  docking  mode  involves 
Gscore  for  representing  binding  affinity  and 
ranking  ligands.  The  Glide  HTVS  mode  of 
docking  was  performed  to  7470  conformers 
and  ranked.  Top  747  ligands  (10%)  were 
selected for subsequent SP docking and ranked 
based  on  SPG Score.  The  top  75  compounds 
were redocked using Glide XP docking method. 
Top  ranked  compounds  obtained  through  XP 
docking were compared favorably  with  XPG 
score  of  15  published  inhibitors 
(Supplementary  Figure  1).  Among  published 
inhibitors, balanol and „796‟ have showed the 
lowest XPG score of -10.63 Kcal/mol. Lead „1‟
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structural features and active site residues of PRKACA-„796‟ Complex. A. Secondary structural elements, 
catalytic residues and ligand contact residues of PRKACA. B. Hydrogen bonding patterns and hydrophobic nteractions of 
„796‟ with PRKACA 
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(leptosidin)  was  found  to  have  better  XPG 
score  than both balanol and hence „796‟  has 
better  binding  affinity  compared  to  the 
existing PRKACA inhibitors. 
PRKACA – leptosidin docking complex 
The virtual screening result showed that, lept 
sidin  (Supplementary  Figure  2)  had  the 
lowest  XPG  score  of  -11.02  Kcal/mol 
(Supplementary  Figure  1)  compared  to  pro- 
posed leads and 15 published inhibitors. The 
good binding affinity of leptosidin is due to 
various  interactions  such  as  hydrogen 
bonding,  hydrophobic  interactions, 
hydrophilic  interact  tions,  electrostatic 
interactions  and  steric  inter  actions.  The 
PRKACA-leptosidin  docked  complex  was 
visualized  in  Figure  2A  and  with  residues 
involved in inter-atomic contact was shown in 
Figure 2B. 
Leptosidin  was  bound  to  PRKACA  with 
five  H  (hydrogen)-bonds  in  addition  to 
hydrophobic  and  van  der  Waal  (vdW) 
interactions  (Figure  2BThe  two  H-atoms 
(17(O) –H and 19(O)–H) of hydroxyl group 
of  leptosidin  catechol  ring  formed  H-bonds 
with backbone atom of polar residue, Thr51 
(1.778  Å)  and  side  chain  atom  of  charged 
Glu127  (1.393  Å).  The  hydroxyl  group 
(5(O)–H) of leptosidin guaiacol ring formed 
two H-bonds with carboxyl group of  Glu121 
(2.304 Å) and hydrophobic group of Val123
(2.02  Å).    Oxygen  atom  (10(O))  of 
leptosidin formed one H-bond with polar side 
chain  hydrogen  of  Thr183  (2.439  Å).  The 
residues Leu49, Gly50, Thr51, Gly52, Gly55, 
Arg56, Ala70, Lys72, Ile73, Leu74, Val103, 
Met120,  Glu121,  Tyr122,  Val123,  Asn171, 
Leu173,  Thr183,  Asp184  and  Phe327  and 
Tyr336  were  involved  with  good  van  der 
Waal interactions with leptosidin. 
Pharmacokinetic properties such as molecular 
weight,  hydrogen  bond  donors,  hydrogen 
bond  acceptors,  logP  (water/octanol),  water 
partition  coefficient  (QPlogPo/w),  water 
solubility  (QPlogS),  permeability  through 
Madin-Darb y  Canine  Kidney  Cells 
(QPlogMDCK), Qik Prop predicted log IC50 
value for  blockage  of  K
+  channels 
(QPlogHERG),  QikProp    predicted    gut- 
blood  barrier  (QPPCaco),  violations  of  the 
Lipinski„s  rule  of  five  (LROF),  cell  perme- 
ability  (QPPCaco)  etc.  are  critical  for 
estimation  of  absorption  and  distribution  of 
drugs within the body, drug metabolism and 
its access to biological membranes.  All these 
values  for  leptosidin  were  well  within  the 
acceptable  range  for  a  drug  with  good 
pharmacological properties (Table 1).  
Molecular dynamics simulations 
Receptor structural rearrangements: Stability 
of PRKACA - leptosidin complex was evalu- 
ated through 10 ns molecular dynamic
 
 
 
Figure  2:  Docking  interactions  of  PRKACA-
leptosidin complex.           
A.  Leptosidin is  interacting   in the largest binding  
pocket of PRKACA.    
B.Interactions  of  PRKACA-leptosidin  docking 
complex. 
 
A 
 
 
 
 
 
 
 
Figure  2:  Docking  interactions  of  PRKACA-
leptosidin complex.           
A.  Leptosidin is  interacting    in  the  largest  binding  
pocket of PRKACA.    
B.Interactions  of  PRKACA-leptosidin  docking 
complex. 
   
B 
 
 
 
 
 
 
 
Figure  2:  Docking  interactions  of  PRKACA-
leptosidin complex.           
A.  Leptosidin is  interacting    in  the  largest  binding  
pocket of PRKACA.    
B.Interactions  of  PRKACA-leptosidin  docking 
complex. 
   Molecular docking & dynamics of PRKACA  Sandeep et al   
simulations.  The  simulations  provided  exact 
binding  interaction  of  the  docking  complex 
with system embedded with water molecules, 
temperature  and  pressure.  The  complex  of 
PRKACA-  leptosidin  was  originated  in  all 
proper  binding  poses  with  an  acceptable 
RMSD value (< 2 Å). RMSD values of the 
protein backbone atoms and the heavy atoms 
of  inhibitor  during  the  production  phase 
relative  to  the  starting  structures  were 
determined and plotted (Figure 3A). 
Table 1: Pharmacokinetic  properties  of  leptosidin 
S.No  Pharmacokinetic 
properties  Values 
1  QPlogMDCK  62.50 
2  QPP Caco  147.4 
3  QPlogPo/w  1.381 
4  QPlogS  -3.95 
5  LogPC  10.316 
6  Oral absorption  73.847 
7  Ligand Efficiency  -0.501 
8  H-bond donors  3 
9  H-bond acceptors  5.5 
10  Molecular weight  300.267 
11  QPlogHERG  -5.176 
12   LROF   0  
RMSD  plot  revealed  that  the  complex  was 
relatively  stable  throughout  the  simulation 
time. The overall RMSD range for backbone 
atoms  were  0.6  –1.8  Å  and  heavy  atoms 
were  0.7  –  2.2  Å.  The  RMSF  values  of 
backbone  and  side  chain  atoms  were 
assessed  for  each  residue  of  PRKACA 
(Figure 3B).  Side chain fluctuations of  90% 
of  residues were  observed within the range 
of  0.5  -  2.0  Å;  94%  of  backbone  residue 
fluctuations were within the range of 0.4 - 1.5 
Å. Side chain of Lys-319 showed a maximum 
fluctuations  of  3  Å.    Maximum  backbone 
fluctuations  up  to  3  Å  was  observed  for 
serine.  Inhibitor  binding  pocket  residues 
showed  comparatively  lower  backbone  and 
side  chain  fluctuations  compared  to  other 
residues.  The  small  range  of  RMSDs  and 
RMSFs  reflected  slight  structural 
rearrangement in the docking complex during 
simulation time. The energy plot showed that 
the  energy  of  the  system  was  relatively 
consistent during 10 ns MD simulations run 
(Figure 3C). 
Interactions of PRKACA-leptosidin 
complex during simulations 
The  influence  of  lead1  on  the  dynamical 
properties of PRKACA active site have been 
clarified  by  analyzing  the  trajectory  data 
obtained  from the MD simulations. The 
PRKACA-leptosidin  docking  interactions 
were reproduced during the entire simulations 
period (Figure 3D). The    analysis revealed 
crucial role of water molecules in PRKACA-
leptosidin  interactions.  In  most  of  the 
trajectories,   active   site  residues  of 
PRKACA  were  involved  in  H-bonding 
through water bridges  (Figure  3D).  The  H- 
bonds observed for Glu-121 and Val-123 in 
the  PRKACA-leptosidin  docking  complex 
remained  stable  throughout  the  simulation 
period  (Figures  3D  and  3E).  Glu-127  was 
observed to form H-bond with leptosidin till 
~2000ps simulation time. In some trajectories 
Glu-127 formed H-bond with the one water 
bridge  (supplementary  Figure  3A)  while  in 
other  trajectories  it  formed  direct  H-bonds 
with  leptosidin  (supplementary  Figures  3B 
and 3C). Thr-51 was also forming hydrogen 
bonding   d u r i n g M D simulations  (supple- 
mentary Figures 3B and 3F). In none of the 
trajectories Thr183-leptosidin H-bond was 
observed.  The analysis revealed existence 
of  additional  H-bonds  between  leptosidin 
and   Glu-170  of  PRKACA 
(supplementary  Figures      D,  E  and  F). 
Suitably, Glu-170 was identified as catalytic 
residue  in  CSA  annotation  of  PRKACA 
(Figure1A).  Final  trajectory  of  PRKACA-
leptosidin complex was found to form 8 H-
bonds (Glu-121, Val-123 directly and Thr-51, 
Pro-169, Glu-170, Leu-172, Tyr-330 through 
water bridges (Figure 3D). 
In  MD  simulations,  solvating  water  mole- 
cules  were  considered  for  checking  the 
stability of ligand-protein complex in contrast 
to molecular docking. MD simulations were 
acknowledged  closer  to  the  physiological 
environmental  conditions  and  it  reveals 
better  binding  conformations  for  docked 
complex. The MD simulations for PRKACA- 
leptosidin  complex  carried  out  almost 
reproduced  the  docking  interaction  pattern 
during  trajectory  analysis.  Additionally  the 
analysis revealed   that the catalytic residue 
Glu-170 was blocked by formation of H-bond 
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between  leptosidin  and  PRKACA.  The 
RMSD, RMSF, potential energy  and 
interactions  of  the  PRKACA-
leptosidin  complex  remained  consistent 
throughout the MD simulations. The complex 
corroborated  well  with  crystallographic 
information  of  PRKACA  in  complex  with 
inhibitor ARC-1034 and 796. 
DISCUSSION 
An elevated level of cAMP dependent protein 
kinase catalytic subunit  alpha in  samples  of 
prostate cancer is representing the protein as a 
drug  target  for  prostate  cancer  therapy.  A 
systematic  virtual  screening  approach  was 
followed in the present study to propose  
 
leptosidin as a potent inhibitor of PRKACA 
from  one  million  small  molecules  of 
Ligand.Info database. The binding modes and 
interactions  of  PRKACA-leptosidin  docking 
complex (Figure  2B)   were   compared with 
crystallographic  data  of  PRKACA-
„796‟complex  (Figures  1A  and  1B). 
Leptosidin  is  a  flavonoid  isolated  from 
Coreopsis grandiflora. Favorable comparison 
of  XPG  score  and  binding  orientations  of 
leptosidin  with  the  „796‟  and  good 
pharmacokinetic  properties  revealed  that  it 
was  better  potential  inhibitor  for  PRKACA 
than the existing inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
   
 
 
 
 
 
 
Figure  3: Interactions of PRKACA-leptosidin complex during 10 ns molecular dynamics simulations run. 
A. RMSD of heavy atoms and back bone atoms. B. RMSF of PRKACA-leptosidin docked complex. C. 
Energy peak of the docked complex. D. PRKACA-leptosidin complex in the last trajectory showing 8 H-
bonds. E. Hydrogen bond distances of Glu 121 and Val 123. 
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Stability  of  docked  complex  was  further 
analyzed  through  the  molecular  dynamic 
simulations  using  Desmond.
24,25  The 
docking and MD simulations studies were 
revealed  that  the  binding  affinity  of 
leptosidin  towards  PRKACA  was  highly 
stable  with  the  proposed  binding 
orientations.  Analysis  of  RMSD,  RMSF, 
potential  energy  and  hydrogen  bonding 
interactions  of  docking  complex  were 
rationalized  that  the  steady  nature  of  the 
lead compound. Active site residues such 
as  Val-123  and  Glu-121  residues  have 
formed  stable  H-bond  in  all  trajectories 
and complex was consistent (Figure 3D). 
Additional  H-bonds  (direct  and  water 
bridges)  were  observed  with  active  site 
residues such as Leu49, Leu-172, Pro-169, 
Glu-170  and  Tyr-330  during  simulation 
time  which  revealed  the  PRKACA-
leptosidin  complex  as  more  stable  in  the 
physiological  environmental  conditions 
(Figure 3D). Finally, the docked result and 
MD simulations proved that leptosidin was 
having better binding orientations, RMSD, 
RMSF,  potential  energy  and  obey  good 
pharmacological  properties.  Therefore  it 
can  be  considered  for  designing  drug 
molecules against prostate cancer.  
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